Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Real-time Estimate Cboe BZX  -  12:15:45 2023-01-30 pm EST
288.29 USD   -0.62%
11:11aGlobal markets live: Toyota, Unilever, Bayer, Goldman Sachs, Biogen...
MS
10:29aUBS Adjusts Biogen's Price Target to $337 From $338, Maintains Buy Rating
MT
09:19aSector Update: Health Care Stocks in Red Pre-Bell Monday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen Shares Fall After Report of Death Linked to Potential Treatment for Alzheimer's Disease

11/28/2022 | 10:42am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -0.39% 288.95 Delayed Quote.4.75%
EISAI CO., LTD. -0.49% 8109 Delayed Quote.-6.38%
All news about BIOGEN INC.
11:11aGlobal markets live: Toyota, Unilever, Bayer, Goldman Sachs, Biogen...
MS
10:29aUBS Adjusts Biogen's Price Target to $337 From $338, Maintains Buy Rating
MT
09:19aSector Update: Health Care Stocks in Red Pre-Bell Monday
MT
09:02aIt's all about central banks this week
MS
04:56aEisai-Biogen Partnership Pursues Marketing Authorization of Alzheimer's Drug in Europe
MT
03:45aBiogen, Eisai Drug Lecanemab Gets Priority Review Status in Japan
MT
01/29Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen
RE
01/29Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen
RE
01/29Lecanemab receives priority review status in japan
PR
01/29Lecanemab Receives Priority Review Status in Japan
GL
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 10 068 M - -
Net income 2022 2 873 M - -
Net Debt 2022 266 M - -
P/E ratio 2022 14,3x
Yield 2022 -
Capitalization 41 772 M 41 772 M -
EV / Sales 2022 4,18x
EV / Sales 2023 4,11x
Nbr of Employees 9 610
Free-Float 85,2%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 290,08 $
Average target price 322,44 $
Spread / Average Target 11,2%
EPS Revisions
Managers and Directors
Christopher A. Viehbacher President, Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors